ArticleJournal for immunotherapy of cancer2018

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.

Lillian Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.